Recruiting
Human papilloma virus immunisation
RecruitingRegistered drugNo placebo
A study on the long-term effectiveness and safety of nine-valent human papillomavirus vaccine in women aged 16 to 26 years for prevention of cervical cancer
Registered drugNo placebo
- Disease:Human papilloma virus immunisation
- Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By RdnaHuman Papillomavirus Type 16 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna+7
Countries:
Norway
Norway- Participants:18–64 years · Healthy volunteers
- Substances:Human Papillomavirus Type 11 L1 Protein - Adsorbed - In The Form Of Virus-Like Particles Produced In Yeast Cells (Saccharomyces Cerevisiae Canade 3C-5 (Strain 1895)) By Rdna
- Sponsor:Merck Sharp & Dohme LLC


